retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial Upcoming wave of hormone-based therapies set to change field of diabetes, care Retatrutide, a TRIPLE agonist (GLP1,

This pressure was felt slightly more by women (62%) than men (59%) and increased in younger generations (Gen Z: 64%, millennials: 67%, Gen X: 55%)

Vision loss concerns throw natural alternatives in the spotlight Fear of side-effects is often only one among several barriers to taking GLP-1 drugs

Health Canada has not authorized any of the products that were seized or sold on the company's website, which means that they have not been assessed for safety, efficacy, and quality

Exploring the hair loss risk in glucagon-like peptide-1 agonists: Emerging concerns and clinical implications

After the plunger is fully depressed or the pen has delivered the full dose, count to 5 while keeping the needle in place